在达标治疗研究中达到与未达到ACR/EULAR布尔缓解的类风湿关节炎患者的炎症与生物制剂治疗
在ARCTIC试验中,203例未用过改善病情抗风湿药的类风湿关节炎患者按现行推荐治疗。2年时112例(55%)达到ACR/EULAR布尔缓解,49例(24%)满足四条中的三条。主要限制因素为患者总体评估(59%)和压痛关节(22%)。未达标者影像学炎症与达标者无显著差异,但使用生物制剂的机会比更高(OR 3.63,95%CI 1.73至7.61)。
要点
- 患者总体评估和压痛关节是ACR/EULAR布尔缓解最常受限的因素。
- 因PGA升高和/或压痛关节未达标者,影像学炎症与达标者无显著差异。
- 未达标者使用生物制剂的机会比更高(OR 3.63,95%CI 1.73至7.61)。
核心结论
- 患者总体评估和压痛关节是最常限制达到ACR/EULAR布尔缓解的因素。
- 这些未达标患者的影像学炎症水平与达标患者相比未升高,但使用生物制剂的机会比更高。
研究设计与样本
- ARCTIC试验(Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen)中未用过改善病情抗风湿药的类风湿关节炎患者,按现行推荐治疗。
- 评估2年时达到ACR/EULAR布尔缓解的限制因素,并比较缓解患者与未满足不同缓解条款患者的超声和MRI炎症,用逻辑回归计算生物制剂治疗的OR。
主要发现
- 203例患者中112例(55%)达到ACR/EULAR布尔缓解,49例(24%)满足四条中的三条。
- 主要限制因素为患者总体评估(59%)和压痛关节(22%)。
- 因患者总体评估升高和/或压痛关节未达标者与达标者相比,影像学炎症无显著差异。
- 未达标者使用生物制剂的机会比更高(OR 3.63,95%CI 1.73至7.61)。
关键数值与推荐
- ACR/EULAR布尔缓解定义为满足四条标准,原文未列出具体条款。
- 203例中112例(55%)达到布尔缓解,49例(24%)满足三条。
- 限制因素中患者总体评估占59%,压痛关节占22%。
- 使用生物制剂的OR为3.63(95%CI 1.73至7.61)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. METHODS: Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. RESULTS: Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. CONCLUSIONS: PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher.
引用
- Paulshus Sundlisæter N, Sundin U, Aga AB, et al. Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. RMD Open. 2022. PMID: 35091463. doi:10.1136/rmdopen-2021-002013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。